PAH and pulmonary arterial hypertension: It is expected that splice suppression of the Pah pre-mRNA will result in a decrease in liver (and kidney) PAH activity that can be easily monitored indirectly by measuring blood L-Phe concentration, now a sensitive biomarker for the effectiveness of this antisense treatment.